The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio.
The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio. The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio. Moneycontrol Latest News Read More
English 
हिन्दी